Although it is a rare disease, the number of available therapeutic options for treating
pulmonary arterial hypertension has increased since the late 1990s, with multiple drugs …

Risk stratification has gained an increasing role in predicting outcomes and guiding the
treatment of patients with pulmonary arterial hypertension (PAH). The most predictive …

Background Achievement of low-risk status is a treatment goal in pulmonary arterial
hypertension (PAH). Risk assessment often is performed using multiparameter tools, such …

Despite the advent of new therapies and improved outcomes in patients with pulmonary
arterial hypertension (PAH), it remains a life-shortening disease and the time to diagnosis …

Pulmonary hypertension (PH) is caused by a range of conditions and is important to
recognize as it is associated with increased mortality. Pulmonary arterial hypertension refers …

Background: Cell-free DNA (cfDNA) is a noninvasive marker of cellular injury. Its
significance in pulmonary arterial hypertension (PAH) is unknown. Methods: Plasma cfDNA …

BACKGROUND Approaches to risk assessment in pulmonary arterial hypertension (PAH)
include the noninvasive French risk assessment approach (number of low-risk criteria based …

Rationale: Exercise capacity predicts mortality in pulmonary arterial hypertension (PAH), but
limited data exist on the routine use of maximal exercise testing. Objectives: This study …

Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH‐
LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial …

Background In pulmonary arterial hypertension, it is recommended to base therapeutic
decisions on risk stratification. This systematic review aims to report the prognostic value of …